Follow
Cytovac AB
Nasdaq First North Sweden (Sweden)
Cytovac is a growing Danish biotech company, which has chosen to focus on development of a cancer treatment that uses the body’s own immune system.
Sector:
HEALTH CARE
Current instruments
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
Nasdaq First North Sweden
Sweden (SE)
Details of share in Cytovac AB with ticker
Status
Active
Order book id
Amount of instruments
Par value
Market cap
Currency
SEK
Segment
First North Premier
Terms
Type
Price
Pre-money valuation
Time
Listing
-
-
2020
Direct listing of Cytovac AB on Nasdaq First North Sweden
Market
Nasdaq First North Sweden
Status
Upcoming
Comment for Listing
Cytovac plans to release an IPO prospectus at the end of April 2019, with a subscription period in May and listing at the end of May.

Update: The company started to market their IPO in April 2019 but cancelled, citing weak market conditions. The company will instead do a private investment round and do an IPO after a Phase II study is finished, which is expected in the summer of 2020.
People
Company Details
Sector
HEALTH CARE

Address
Zip code
City/district
Country
Sweden (SE)
Phones
Email
Registration number
559162-3318
LEI code
First trade date
Registration date
Short name
Cytovac